Volume: 2 Issue: 1 (2024) Serial Number: 2

The Hubble tension — the persistent and now ≥5σ disagreement between the Hubble constant H₀ inferred from the cosmic microwave background under ΛCDM (H₀ = 67.4 ± 0.5 km s⁻¹ Mpc⁻¹; Planck 2018, Aghanim et al., 2020) and the value from the local Cepheid–TypeIa-supernova distance ladder (H₀ = 73.04 ± 1.04 km s⁻¹ Mpc⁻¹; SH0ES, Riess et al., 2022) — has, over 2016–2023, moved from a curiosity at the boundary of observational cosmology to one of the principal candidate signatures of physics beyond ΛCDM. Independent corroboration of the local high value by strong-lensing time delays (H0LiCOW: 73.3⁺¹·⁷₋₁·₈; Wong et al., 2020) and megamaser distances (Megamaser Cosmology Project: 73.9 ± 3.0; Pesce et al., 2020), together with the intermediate Tip-of-Red-Giant-Branch value (69.8 ± 1.9; Freedman et al., 2019; Freedman, 2021) and the GW170817 standard-siren measurement (70.0⁺¹²·⁰₋₈·₀; Abbott et al., 2017), have produced a multi-probe landscape that ΛCDM cannot simultaneously accommodate within its uncertainty budget. The Di Valentino et al. (2021) review catalogued the breadth of the theoretical response across more than a thousand proposals; the Kamionkowski–Riess (2023) synthesis identified early dark energy as the most credible single-class resolution; the Schöneberg et al. (2022) “H0 Olympics”provided the first systematic comparative ranking against multidataset constraints. The dialectical question remaining at the December 2023 boundary is which resolution pathway is best supported when CMB, BAO, supernova, structure-growth, and lensing constraints are jointly considered. The original contribution of this article is the Hubble Tension Resolution Pathway Index (HTRPI), a normalised composite metric bounded on [0,1] that integrates five evaluation dimensions — CMB compatibility, BAO compatibility, S₈/structuregrowth compatibility, predictive distinctness from ΛCDM, and theoretical motivation strength — and returns a quantitative ranking of five canonical pathway classes (pre-recombination early dark energy, late-time dark-energy modifications, sound-horizon modifications, local-physics systematic resolutions, and new dark-sector interactions). Applied to the 2016–2023 data, HTRPI returns the highest value for early dark energy (≈0.50), intermediate values for sound-horizon modifications (≈0.42) and new dark-sector interactions (≈0.38), and lower values for late-time dark-energy modifications (≈0.32) and local-physics resolutions (≈0.28).

The first 18 months of routine James Webb Space Telescope (JWST) science operations (July 2022–December 2023) generated the highest-quality exoplanet atmospheric spectra in the history of the field and, with them, the first JWST-era biosignature claims requiring formal evidentiary evaluation. The September 2023 Madhusudhan et al. report of methane (CH₄) at 5σ and carbon dioxide (CO₂) at 3σ in the atmosphere of the habitable-zone sub-Neptune K2- 18b, together with a tentative 1–2σ detection of dimethyl sulfide (DMS) — a molecule whose terrestrial atmospheric production is dominated by marine microbial activity — placed the Madhusudhan–Piette–Constantinou (2021) Hycean-world hypothesis at the centre of an emerging biosignature-evaluation debate (Madhusudhan et al., 2023, 2021). The K2-18b case is, on the 2023 evidence, the first JWST-era exoplanet for which a biosignature claim has been formally articulated in the peer-reviewed literature, but not the only relevant result: the WASP39b Early Release Science programme delivered four parallel Nature papers establishing the JWST atmospheric-characterisation methodology, including the first detection of photochemically produced SO₂ in an exoplanet atmosphere (Ahrer et al., 2023; Rustamkulov et al., 2023; Alderson et al., 2023; Feinstein et al., 2023; Tsai et al., 2023), while the TRAPPIST-1 characterisation (Greene et al., 2023; Zieba et al., 2023; Lim et al., 2023) constrained rocky-planet atmospheric retention around late-type M-dwarf stars. The Schwieterman et al. (2018), Catling et al. (2018), Meadows et al. (2018), and Krissansen-Totton et al. (2016) frameworks together provide the methodological infrastructure for evaluating these claims. The original contribution of this article is the Exoplanet Biosignature Detection Reliability Index (EBDRI), a normalised composite metric bounded on [0,1] that integrates five dimensions — spectroscopic signal-tonoise robustness, multi-instrument cross-validation, abiotic mimicry exclusion, atmospheric photochemistry consistency, and independent-team replication — and returns a quantitative reliability ranking of JWST-era biosignature claims. Applied to the 2023 dataset, EBDRI returns moderate values for the K2-18b CH₄ and CO₂ detections (≈0.55–0.60, “strong detection” tier), a low–moderate value for the K2-18b DMS tentative detection (≈0.30, “contested” tier), a high value for the WASP-39b CO₂ detection (≈0.75, “robust detection” tier), and low values for currently claimed TRAPPIST-1 biosignature features (uniformly < 0.30).

The two-decade arc of quantum-biology research on photosynthetic energy transfer has, over 2016–2023, undergone a substantial empirical and theoretical reassessment. The 2007 Engel et al. Nature observation of long-lived coherent oscillations in the Fenna–Matthews–Olson (FMO) complex at 77 K, followed by the Panitchayangkoon et al. (2010) demonstration that comparable oscillations persisted at physiological temperatures (277 K), generated the influential “warm and wet” hypothesis: that photosynthetic light-harvesting complexes exploit long-lived electronic quantum coherence to achieve near-unity energy-transfer efficiency, operating outside the conventional thermal-noise regime where decoherence should rapidly destroy electronic superpositions. The subsequent reassessment — anchored by Duan et al. (2017), who showed that electronic decoherence in FMO occurs within 60 fs at physiological temperatures, Thyrhaug et al. (2018a), and the Cao et al. (2020) 18-author consensus review “Quantum biology revisited” — has shifted the working consensus toward the interpretation that the long-lived oscillations originally attributed to electronic coherence are dominated by impulsively excited vibrational coherences rather than functionally relevant electronic superpositions. Wilkins & Dattani (2020) further argue that even if some inter-exciton coherences persist, they do not measurably enhance energy-transfer efficiency above incoherent Förster-type predictions. The Mirkovic et al. (2017) comprehensive review provides the framework against which the post-2016 reassessment is interpreted. The principal aim of this article is to formalise the cross-claim evaluation of the surviving quantum-coherence proposals through the Photosynthetic Coherence Functional Relevance Index (PCFRI), a normalised composite metric bounded on [0,1] that integrates five evaluative dimensions — spectroscopic detection robustness, origin specificity, decoherence-vsenergy-transfer timescale ratio, functional-role demonstration, and in-vivo relevance gap — and returns a quantitative ranking of competing claims. Applied to five canonical claim categories, PCFRI returns values in the 0.15–0.50 range, indicating that no current quantum-coherence proposal achieves the “demonstrated functional relevance” tier and that the post-2016 reassessment has, on the PCFRI calibration, empirically vindicated the sceptical position of Wilkins & Dattani (2020).

The publication of the telomere-to-telomere CHM13 sequence (Nurk et al., 2022) and the first draft Human Pangenome Reference (Liao et al., 2023) jointly mark the end of the linear single-reference paradigm that has governed human genomics for two decades. GRCh38 omits roughly 200 megabases of repetitive and acrocentric sequence and carries a documented European-ancestry bias; the new resources close most of that gap and reframe the reference itself as a structured graph over 47 phased haplotypes spanning multiple ancestry groups. This article addresses a question that the celebratory tone of the original announcements largely sidestepped: how mature is the actual transition? We propose the Pangenome Adoption-Readiness Transition Index (PARTI), a normalized composite metric on [0,1] that aggregates five dimensions of practical readiness — reference completeness gain (D_comp), population and ancestry representation (D_pop), toolchain native-graph support (D_tool), clinical-pipeline integration (D_clin), and variant-call equivalence relative to legacy reference workflows (D_eq) — into a single comparable score via geometric mean. PARTI is applied to five canonical use-cases: germline short-variant calling, structural-variant detection, repeat-rich and segmental-duplication analysis, pharmacogenomic interpretation, and clinical diagnostic pipelines for rare disease and oncology. Resulting scores range from 0.62 (structural-variant detection, the largest immediate win) down to 0.21 (clinical diagnostic pipelines, the slowest mover). The analysis identifies clinical-pipeline integration (D_clin) as the binding constraint across four of five use-cases: graphnative variant callers exist, but the regulatory, interpretive, and infrastructure layers — variant databases, ACMG/AMP guideline operationalization on a graph reference, electronic-healthrecord liftover, and laboratory information-management-system compatibility — remain calibrated to GRCh38. PARTI thus reframes the transition as a stratified engineering and policy problem rather than an undifferentiated paradigm shift, and identifies the specific subsystems on which the practical end of the single-reference paradigm is contingent.

Transgenerational epigenetic inheritance (TGEI) in mammals — the transmission of phenotype-relevant epigenetic information from an exposed F0 generation to unexposed F3 (maternal lineage) or F2 (paternal lineage) generations through germline mechanisms — has, in the 2016-2022 window, accumulated a substantial empirical literature spanning at least five candidate molecular carrier classes: residual DNA methylation surviving the two genome-wide reprogramming events, sperm-borne transfer-RNA-derived small RNAs (tsRNAs) and their post-transcriptional modifications, sperm microRNAs (miRNAs), retained histone posttranslational modifications at sperm-resistant loci, and higher-order chromatin-architecture features including topologically associating domains and centromeric heterochromatin organisation. Each carrier class has accumulated its own evidentiary profile across detection robustness, reprogramming-bypass mechanism, zygote-rescue causality, cross-species evolutionary conservation, and therapeutic-translation actionability. The literature has, however, been organised predominantly around specific phenomenological claims — paternal-diet metabolic inheritance, paternal-stress behavioural inheritance, Holocaust FKBP5 trauma transmission, gestational-famine epigenetic imprints — rather than around the molecular carriers themselves. The companion article in this series introduced the Mammalian Transgenerational Epigenetic Inheritance Evidence Index (MTEII) to evaluate the claim-level evidentiary strength of specific TGEI cases; the present review introduces, as the complementary original contribution, the Transgenerational Carrier-Mechanism Sufficiency Index (TCMSI), a normalised composite metric — bounded on [0,1] — that integrates five carrier-mechanism dimensions (detection robustness in mammalian germline, reprogramming-bypass mechanism specificity, demonstrated zygote-rescue causality, inter-species evolutionary conservation, and therapeutictranslation actionability) and returns a quantitative ranking of the five carrier classes on a metric explicitly designed to evaluate molecular-mechanism sufficiency rather than claim-level evidentiary support. Applied to the five canonical carrier classes, TCMSI returns the highest score for sperm tsRNAs and their DNMT2-mediated modifications (≈0.62), intermediate scores for sperm miRNAs (≈0.55) and residual DNA methylation (≈0.42), and lower scores for retained histone modifications (≈0.35) and higher-order chromatin architecture (≈0.28).

The linker of nucleoskeleton and cytoskeleton (LINC) complex — composed of SUNdomain proteins traversing the inner nuclear membrane and KASH-domain nesprins traversing the outer nuclear membrane, together physically coupling the cytoskeleton to the nuclear lamina and chromatin — has, over the 2016-2023 window, moved from a structurally-characterised molecular assembly to a central explanatory node in a broad family of mechanopathologies. Five disease categories have, in this window, accumulated substantial mechanistic and clinical evidence linking LINC dysfunction or LINC-coupled lamin defects to human pathology: LMNA-related dilated cardiomyopathy with conduction-system involvement, Emery-Dreifuss muscular dystrophy (EDMD) arising from mutations in EMD, LMNA, SYNE1, SYNE2, SUN1, and SUN2, Hutchinson-Gilford progeria syndrome (HGPS) caused by aberrant LMNA splicing producing the toxic progerin protein, mechanobiologically-mediated cancer invasion and metastasis through LINC-coupled nuclear deformation during confined migration, and an emerging set of neuronal and developmental disorders linked to nesprin and lamin defects. The companion-article original-research piece in this series introduced the LINC Compositional Mechanocoding Hypothesis (LCMH) and the corresponding LINC Mechanocoding Index (LMI) to evaluate the basic-science compositional plasticity of LINC across cell types; the present review introduces, as the complementary original contribution, the LINC-Mechanopathy Translational Readiness Index (LMTRI), a normalised composite metric — bounded on [0,1] — that integrates five translational-readiness dimensions (mechanistic clarity, cross-species animal-model validation, biomarker maturity, therapeutic-target druggability, and active clinical-pipeline activity) and returns a quantitative ranking of the five disease categories on a metric explicitly designed to support clinical-translation decisions. Applied to the five canonical disease categories, LMTRI returns the highest readiness score for Hutchinson-Gilford progeria syndrome (≈0.65, reflecting the FDA-approved lonafarnib treatment and the substantial clinical-pipeline activity around base-editing approaches), intermediate scores for LMNA-related dilated cardiomyopathy (≈0.50) and Emery-Dreifuss muscular dystrophy (≈0.45), and lower scores for LINC-mediated cancer invasion (≈0.35) and emerging neuronal disorders (≈0.28).